Andrew Obenshain, bluebird bio CEO

Zyn­te­glo and Skysona com­bine for 16 pa­tient starts since ap­provals last year

Blue­bird bio’s gene ther­a­py Zyn­te­glo, which was ap­proved by the FDA to treat pa­tients with trans­fu­sion-de­pen­dent tha­lassemia last Au­gust, hasn’t had many tak­ers.

Blue­bird said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.